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Abstract
Background: There seems to be no consensus concerning taking bladder biopsies during transurethral resection of 
bladder tumor (TUR-BT). We investigate the clinical significance of bladder biopsy with TUR-BT and the relationship 
between urinary cytology and the biopsy results.
Methods: We reviewed a total of 424 patients with non-muscle invasive bladder cancer treated with TUR-BT between 
1998 and 2005. Of the total, 293 patients also underwent a bladder biopsy. Biopsies from suspicious-appearing 
urothelium (N = 59) and those from normal-appearing urothelium (N = 234) were evaluated separately.
Results: Bladder cancer was observed in 23 cases (39.0%) who underwent a biopsy of suspicious-appearing 
urothelium. Among these 23 cases, 9 cases with visible tumor resection had carcinoma in situ (CIS) only in the biopsies 
from suspicious-appearing urothelium. Urinary cytology was negative in 3 of the 9 cases. Bladder cancer was observed 
in 26 cases (11.1%) who underwent a biopsy of normal-appearing urothelium. Of them, 5 cases with visible tumors had 
CIS only in the multiple biopsies from normal-appearing urothelium. Urinary cytology was positive in all of the 5 cases. 
No upstaging or upgrading cases were found in these patients by the addition of these two types of biopsy. 
Furthermore, therapy was not altered in these patients. With or without bladder biopsy was not a significant factor for 
tumor recurrence in either the univariate or multivariate analysis.
Conclusions: Based on the results, it is concluded the multiple biopsies from normal-appearing urothelium are not 
necessary in patients with negative cytology results because of the low detection rate and lack of influence on 
therapeutic decisions. Meanwhile, biopsy of suspicious-appearing urothelium is needed in patients with negative 
cytology results in order to detect CIS due to staging properties. This result supports a recent EAU guideline.
Background
Bladder cancers are classified as being non-muscle-inva-
sive or muscle invasive according to their histological
appearance. Non-muscle-invasive bladder cancers
account for about 70 to 80% of all bladder cancers[1-4].
Non-muscle-invasive tumors have a heterogeneous clini-
cal course ranging from low-grade Ta tumors to highly
malignant Tis and T1 lesions[5-7]. Low-grade carcinomas
rarely exhibit progression. However, high-grade carcino-
mas do recur within a short period and sometimes invade
the muscle layer, necessitating a change in treatment[7].
The primary approach for Ta and T1 tumors is transure-
thral resection of bladder tumor (TUR-BT). The main
problem after the initial treatment of non-muscle-inva-
sive bladder cancers is the high recurrence rate. Approxi-
mately 40 to 80% of Ta-T1 tumors recur after the initial
treatment[2]. Many prognostic factors, such as tumor
stage, tumor grade, multiplicity, concomitant carcinoma
in situ (CIS), and tumor size have been proposed to affect
tumor recurrence of non-muscle-invasive bladder carci-
nomas[6,8-11]. Some reports have suggested the impor-
tance of biopsy of bladder mucosa from normal
appearing urothelium or from reddish areas at the time of
initial treatment for bladder carcinoma as an additional
biopsy might improve the diagnostic accuracy for bladder
cancer staging and alter the therapeutic option for the
tumor[7,8,10,12,13]. Meanwhile, an EAU guideline sug-
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gested that routine random biopsy is not advised if blad-
der mucosa has a normal aspect and urine cytology is
negative. Furthermore, other investigators have suggested
the possibility that bladder biopsies induce implantation
of tumor cells at the biopsied mucosal site[6,7,10,14-17].
Still, there seems to be no consensus concerning taking
bladder biopsies during TUR-BT[2,4,10].
In the present study, we evaluated 1) the clinical signifi-
cance of bladder biopsies from suspicious-appearing
urothelium and multiple biopsies from normal-appearing
urothelium separately, 2) not only tumor up-staging but
also up-grading of these biopsies, 3) the relationship
between urinary cytology and biopsy results, 4) its impact
on further treatment decision-making, and 5) whether or
not additional bladder biopsies promote the intravesical
recurrence of bladder carcinoma.
Methods
Between 1998 and 2005, 424 patients with non-muscle
invasive bladder cancer were treated with TUR-BT at
Keio University Hospital in Tokyo. The mean age of the
patients was 68.7 ± 0.57 (25-92) years old. The patients
consisted of 349 men and 75 women. The median follow-
up period was 3.6 ± 0.1 years. Bladder biopsies in 59
patients had been performed from reddish or mossy
areas apart from the main tumor and edema of the blad-
der mucosa (biopsy from suspicious-appearing urothe-
lium). Multiple biopsies of apparently normal mucosa
were performed systemically in 234 patients (multiple
biopsies from normal-appearing urothelium) during
TUR-BT. Thirty-four patients underwent both a biopsy
from suspicious-appearing urothelium and multiple
biopsies from normal-appearing urothelium. Thus, a
total of 293 patients underwent bladder biopsies. Basi-
cally, all patients with reddish or mossy areas apart from
the main tumor and edema of the bladder mucosa under-
went biopsy from suspicious-appearing urothelium.
Meanwhile, multiple biopsies from normal-appearing
urothelium were performed based upon the decision of
the attending doctor. Multiple biopsies from normal-
appearing urothelium were carried out to examine the
following 6 cystoscopically normal-appearing bladder
mucosal sites: (1) bladder floor, (2) right wall, (3) left wall,
(4) dome, (5) posterior wall, and (6) prostatic urethra (in
males) or bladder neck (in females).
The study was conducted subject to the guidelines of
the Declaration of Helsinki and had no influence on the
treatment of the patients. Keio university hospitals ethical
committee granted ethical approval for the study. We
obtained the patients' informed consent to carry out the
surgery including their approval for potential use of their
anonyms medical data from our data base for research
and audit purposes.
Patient characteristics, including age, sex, tumor grade,
initial number of tumors, pathological stage, the presence
of CIS, and preoperative cytology were determined. If the
urinary cytology was class III or greater, it was defined as
positive.
BCG was scheduled for weekly administration for 6
weeks for stage Ta-T1 tumors and for 8 weeks for CIS at a
dose of 80 mg of Tokyo strain or 81 mg of Connaught
strain of BCG in 40 mL of saline instilled into the bladder
by way of an 8 Fr urethral catheter, with retention for 1-2
hours.
These patients were assessed by urine cytology and cys-
toscopy every 3 months for 2 years after the initial treat-
ment, every 6 months for the next 3 years, and then yearly
thereafter. Intravenous urography or ultrasonography
and/or CT scanning was used to evaluate the bladder and
kidneys every 6 months for 5 years after the initial treat-
ment, and then yearly thereafter. Histopathological
extensions and grade were classified according to the
TNM classification 1997[18] and WHO grading
1999[19].
The indicators of intravesical recurrence risks due to
bladder biopsies were analyzed using univariate and mul-
tivariate Cox regression models. Indicators including sex,
first or 2 or more TUR, grade, multiplicity, T stage, BCG
therapy, presence of CIS, and enforcement of bladder
biopsy were also analyzed.
Results
The pathological characteristics of the main bladder can-
cers in the TUR-BT specimens of the 424 patients are
listed in Table 1. One hundred and twenty-six cases
(29.7%) were T1 and 144 cases (33.9%) consisted of a G3
element. Solitary tumors and primary cases were
observed in 45.0% and 50.2%, respectively. In total, blad-
der biopsies were performed in 293 patients. Biopsy from
suspicious-appearing urothelium and multiple biopsies
from normal-appearing urothelium were performed in 59
patients (Table 2) and in 234 patients (Table 3), respec-
tively. Both biopsies were performed in 34 patients.
The pathological results of biopsies from suspicious-
appearing urothelium in 59 patients are shown in Table 2.
No tumor was found in 36 patients (61.0%), and urothe-
lial bladder cancer was observed in 23 patients (39.0%). In
the biopsies, TaG2 tumor was observed in 5 patients,
TaG3 tumor in 3 patients, T1G2 tumor in 1 patient, T1G3
tumor in 1 patient, and a CIS lesion in 13 patients. No T2
tumor was detected in the biopsies. Of the 59 cases,
45.7% were urinary cytology negative. No upstaging or
upgrading cases were found in these patients based on
these biopsy results. Nine cases with visible tumors
resected (TaG2:2, TaG3:3, T1G2:1, T1G3:3) had CIS only
in the biopsies from suspicious-appearing urothelium.Matsushima et al. BMC Urology 2010, 10:12
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Urinary cytology was negative in 3 of the 9 cases who had
CIS only in biopsies from suspicious-appearing urothe-
lium (Table4). Four cases were recognized as multiple
tumors based on the additional information obtained
from the biopsies. Urinary cytology was negative in 2 of
the 4 cases who recognized as multiple tumors based on
the additional biopsies from suspicious-appearing
urothelium. Ultimately, 13 cases (22.0%) with TUR plus
biopsies from suspicious-appearing urothelium were
diagnosed as having more malignant features, including
CIS and multiplicity, than that in the TUR specimen
alone. Based on the biopsies from suspicious-appearing
urothelium, therapy was not altered in any of the 13
patients.
In 34 patients who underwent biopsies from suspi-
cious-appearing urothelium and multiple biopsies from
normal-appearing urothelium, no tumor was observed in
the biopsies from normal-appearing urothelium.
The pathological results for 234 patients who received
multiple biopsies from normal-appearing urothelium
alone with TUR-BT are summarized in Table 3. No
tumor was found in the multiple biopsies from normal-
appearing urothelium of 208 patients (88.9%). Urothelial
bladder cancer was observed in 26 patients (11.1%, TaG1:
1, TaG2: 4, TaG3: 8, T1G2: 2, T1G3: 2, CIS: 9). Of these
234 cases, 62.4% were urinary cytology negative. No T2
tumor was detected in the biopsies. No upstaging or
upgrading cases were found. Five cases with visible
tumors (TaG3: 3, T1G3: 2) had CIS only in the multiple
biopsies from normal-appearing urothelium (Table 4). In
these 5 cases, no patient had a negative cytology result.
Three cases were recognized as multiple tumors based on
the addition of multiple biopsies from normal-appearing
urothelium with TUR (T1G3: 3). In these 3 cases, no
patient had a negative cytology result. Ultimately, 8 cases
( 3 . 4 % )  w i t h  T U R  p l u s  m u l t i p l e  b i o p s i e s  f r o m  n o r m a l -
appearing urothelium were diagnosed as having more
malignant features, including CIS and multiplicity, than
the TUR specimens alone. Altogether, due to the biopsies
from suspicious-appearing urothelium, therapy was not
altered in any of the 8 patients.
We stated the differences in the backgrounds of
patients who underwent biopsy and those who did not
(Table 5). As shown in Table 5, age, sex, solitary or multi-
ple, stage, grade, and with or without BCG therapy were
not different between the patients who did and did not
undergo biopsies. The patients with primary tumor
underwent bladder biopsies more frequently than the
patients with recurrence tumor. The results of analysis of
factors affecting intravesical recurrence using Cox's pro-
portional hazards model are shown in Table 6. Univariate
a na lys is  s howed t ha t  ins ti lla t ion o f  BCG,  t u m or gr ade ,
tumor stage, multiplicity, and recurrent cases were signif-
icant prognostic factors for intravesical recurrence (p <
0.05). Multivariate analysis demonstrated that instillation
of BCG, tumor stage, multiplicity, and recurrent cases
were significant prognostic factors for tumor recurrence.
Whether or not a bladder biopsy was performed was not
a significant factor in either the univariate or multivariate
analysis. As shown in the Figure 1, the recurrence rate
was not different between the patients who did or did not
undergo bladder biopsy either at an early time point or
later time point.
Discussion
The clinical significance of multiple biopsies from nor-
mal-appearing urothelium is still controversial. Several
studies have demonstrated the usefulness of multiple
biopsies from normal-appearing urothelium[6,10,13,20].
Recently, May et al. reported that the normal-appearing
urothelium of 128 patients (12.4%) with non-muscle-
invasive bladder carcinoma had cancer tissue[6]. Among
these 128 patients, 58.6% were recognized as upstaging
and therapy was altered in 54.6% based on the results of
the multiple biopsies from normal-appearing urothelium
in addition to the results of the TUR specimen. The
authors concluded that multiple biopsies from normal-
Table 1: Tumor characteristics of the visible tumors 
resected (TUR specimens) in 424 patients
Primary pathology in TUR Total (%)
TaG1 33 (7.8)
TaG2 189 (44.6)
TaG3 62 (14.6)
T1G1 5 (1.2)
T1G2 39 (9.2)
T1G3 82 (19.3)
CIS 14 (3.3)
Solitary 191 (45.0)
Multiple 233 (55.0)
Primary 213 (50.2)
Recurrence 211 (49.8)
Total 424 (100)Matsushima et al. BMC Urology 2010, 10:12
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appearing urothelium had a strong impact on the choice
of the therapeutic strategy for the patient. In contrast,
some investigators believe that multiple biopsies from
normal-appearing urothelium are unnecessary because of
the low incidence of positive biopsy[2,4]. One of the most
important studies on taking multiple biopsies from nor-
mal-appearing urothelium in non-muscle-invasive blad-
der cancer was performed by the European Organization
for Research and Treatment of Cancer (EORTC)[4]. In
the EORTC No. 30863-protocol, 393 patients with soli-
tary and T a or T1 tumors (low risk tumors) underwent
multiple biopsies from normal-appearing urothelium and
CIS was detected in only 6 patients (1.5%). In the EORTC
No. 30911-protocol, multiple biopsies from normal-
appearing urothelium were taken from 602 patients with
multiple or recurrent Ta or T1 tumors (intermediate and
high risk tumors), and 21 patients (3.5%) showed CIS in
multiple biopsies from normal-appearing urothelium. An
unexpected invasive tumor (T2) in a biopsy specimen
was found in only one patient in this series. The EORTC
results suggest that performing multiple biopsies from
normal-appearing urothelium during TUR will not help
with respect to staging and selecting adjuvant therapy
after transurethral resection because of the low incidence
of CIS and cases in which the therapy was altered. While
the outcome of urinary cytology has great impact on the
decision about performing the biopsies and determina-
tion of the stage and/or grade of bladder cancer, the
results of urinary cytology were not mentioned in their
reports.
In the present study, cancer tissue was detected in the
multiple biopsies from normal-appearing urothelium in
26 patients. No up-staging cases were found. We also
focused on tumor grading in this study. In these cases, no
up-grading was found. Furthermore, all 5 CIS cases that
were only detected in the multiple biopsies from normal-
appearing urothelium had positive cytology results.
Three cases were recognized as multiple tumors by also
performing multiple biopsies from normal-appearing
urothelium. These three cases had positive cytology
results. In total, 8 cases were recognized as having more
malignant features, including CIS and multiplicity, due to
the biopsy results. As all of these cases had visible T1 or
high grade or multiple tumors in the TUR specimen, they
were treated with BCG instillation according to the TUR
results. Therefore, therapy was not altered based on the
biopsy results. Furthermore, no case with a T2 specimen
was found in the multiple biopsies from normal-appear-
ing urothelium. Taken together, multiple biopsies from
normal-appearing urothelium did not provide any further
information to assist with the treatment decision. Thus,
we conclude that multiple biopsies from normal-appear-
Table 2: Pathological results of biopsy from suspicious-appearing urothelium in 59 cases
TUR specimen (n) Biopsy from suspicious-appearing urothelium Total (%)
TaG1 TaG2 TaG3 T1G1 T1G2 T1G3 CIS
T a G 1 ( 1 ) 000000 0 0 ( 0 )
T a G 2 ( 2 3 ) 050000 2 7 ( 3 0 . 4 )
T a G 3 ( 1 3 ) 001000 3 4 ( 3 0 . 8 )
T 1 G 1 ( 0 ) 000000 0 0 ( 0 )
T 1 G 2 ( 3 ) 000010 1 2 ( 6 6 . 7 )
T 1 G 3 ( 1 2 ) 002001 3 6 ( 5 0 . 0 )
C I S ( 7 ) 000000 4 4 ( 5 7 . 1 )
T o t a l ( 5 9 ) 053011 1 3 2 3 ( 3 9 . 0 )
P o s i t i v e  c y t o l o g y ( 3 2 ) 042011 8 1 6 ( 5 0 . 0 )
N e g a t i v e  c y t o l o g y ( 2 7 ) 011000 5 7 ( 2 5 . 9 )Matsushima et al. BMC Urology 2010, 10:12
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ing urothelium in negative cytology cases would not be of
any real benefit.
In our study, biopsies from suspicious-appearing
urothelium were performed in 59 cases, and cancer tissue
(no up-staging case and up-grading were found) was
detected in 23 patients (38.9%) and CIS was detected in
13 patients (22.0%). Nine cases had CIS only in the biop-
sies from suspicious-appearing urothelium. Of these 9
cases, 3 patients had negative cytology results. Alto-
gether, 13 cases who underwent biopsies from suspi-
Table 3: Pathological results of multiple biopsies from normal-appearing urothelium in 234 cases
TUR specimen (n) Multiple biopsies from normal-appearing urothelium Total (%)
TaG1 TaG2 TaG3 T1G1 T1G2 T1G3 CIS
T a G 1 ( 2 0 ) 000000 00 ( 0 )
T a G 2 ( 1 0 1 ) 130000 0 4 ( 4 . 0 )
T a G 3 ( 3 4 ) 005000 3 8 ( 2 3 . 5 )
T 1 G 1 ( 4 ) 000000 00 ( 0 )
T 1 G 2 ( 2 2 ) 000010 0 1 ( 4 . 5 )
T 1 G 3 ( 4 8 ) 013012 2 9 ( 1 8 . 8 )
C I S ( 5 ) 000000 4 4 ( 8 0 . 0 )
T o t a l ( 2 3 4 ) 148022 9 2 6 ( 1 1 . 1 )
P o s i t i v e  c y t o l o g y ( 8 8 ) 116002 8 1 8 ( 2 0 . 5 )
N e g a t i v e  c y t o l o g y  ( 1 4 6 ) 032020 1 8 ( 5 . 5 )
Table 4: CIS detected only in bladder biopsy specimen
TUR-BT specimen Number of Pt
biopsies from suspicious-appearing urothelium & positive cytology pTaG2 2
pTaG3 1
pT1G2 1
pT1G3 2
multiple biopsies from normal-appearing urothelium & positive cytology pTaG3 3
pT1G3 2
biopsies from suspicious-appearing urothelium & negative cytology pTaG3 2
pT1G3 1
multiple biopsies from normal-appearing urothelium & negative cytology 0
total 14
Pt: patientMatsushima et al. BMC Urology 2010, 10:12
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cious-appearing urothelium were diagnosed as having
more malignant features than that in the TUR specimen
alone. However, almost all of these cases had visible T1 or
high grade or multiple tumors in the TUR specimen.
Since this was the same result as for multiple biopsies
from normal-appearing urothelium, a change in clinical
treatment based on the biopsies from suspicious-appear-
ing urothelium was not undertaken in these 13 cases in
our hospital.
Table 5: The comparison of clinical characteristics and primary pathology between TUR-BT with or without bladder 
biopsy
Without bladder Bx (TUR-BT only) With bladder Bx P value
Sex
Male 114 235 0.089
Female 17 58
Age
< 65 43 108 0.473
≥65 88 185
Tumor
Solitary 57 134 0.670
Multiple 74 159
TUR-BT
Primary 42 171 < 0.001
Recurrence 89 122
Stage
Ta 92 192 0.542
T1 37 89
Grade
G1 13 25 0.702
G2, G3 116 256
Post BCG
+ 43 120 0.112
-8 8 1 7 3
Bx; biopsy
Table 6: Analysis of factors affecting intravesical recurrence
Univariate analysis
(p value)
Multivariate analysis
(p value)
Standard error Hazards ratio
male vs. female 0.6452
primary vs. recurrence 0.0001 0.0003 0.153 1.737
solitary vs. multiple 0.0020 < 0.0001 0.155 1.853
G1/2 vs. G3 0.0405
Ta vs. T1 0.0344 0.0009 0.156 1.678
with or without BCG Tx < 0.0001 < 0.0001 0.159 2.143
presence or absence of CIS 0.2414
with or without bladder Bx 0.6943
TUR: transurethral resection
Tx: treatment
Bx: biopsyMatsushima et al. BMC Urology 2010, 10:12
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The bladder mucosa after intravesically administered
BCG or chemotherapy mimics the irregular carcinoma-
tous mucosa. In our population, 6 patients underwent
biopsy from suspicious-appearing urothelium within 6
months after BCG therapy. Three of these patients had
positive results (2 patients; CIS, 1 patient; Ta on the
biopsy specimen). Therefore, the other 3 patients had no
malignancy in their biopsy specimens. Two patients
underwent biopsy of suspicious-appearing urothelium
within 6 months after intravesical chemotherapy. These
patients had no malignancy in their biopsy specimens.
The EAU guideline states that, except for a papillary
tumor, if the rest of the bladder mucosa appears normal
and if urine cytology is negative, it is not advisable to rou-
tinely perform multiple biopsies from normal-appearing
urothelium because the likelihood of detecting CIS is
extremely low and the choice of adjuvant intravesical
therapy is not influenced by the biopsy result. This rec-
ommendation of the EAU guideline is based on the
EORTC study[1-4]. However, this study did not fully ana-
lyze the relationship between urine cytology and CIS
detection. In our series, all CIS cases detected only in the
multiple biopsies from normal-appearing urothelium had
positive cytology results. On the other hand, the positive
rate for detecting CIS (22.0%) in biopsies from suspi-
cious-appearing urothelium is significantly higher than
that of multiple biopsies from normal-appearing urothe-
lium (3.8%). Thus, if the patients have suspicious-appear-
i n g  u r o t h e l i u m  o r  pos i t i v e  cyt o l ogy  r e s u l ts,  w e  be l i ev e
that bladder biopsy may be useful for detecting CIS
because of staging properties. This result supported the
recommendations of the EAU guideline.
Several reports have suggested that bladder biopsy
provokes implantation of tumor cells in biopsy
sites[6,7,10,14-17]. Levi et al. reported that cold-cup
bladder biopsy was highly associated with CIS recurrence
compared to hot wire loop biopsy , and thus concluded
that bladder biopsy provokes implantation of neoplastic
cells[15]. In contrast, our univariate and multivariate
analyses demonstrated that performing bladder biopsy in
addition to TUR-BT was not a significant risk factor for
tumor recurrence. As shown in Figure 1, the recurrence
rate was not different between patients with or without
bladder biopsy at either an early time point or late time
point.
There are several limitations to our study. First, the
results were analyzed in a retrospective fashion. There is
also a lack of reproducibility in the determination of his-
tological aberrations such as dysplasia, metaplasia, and
hyperplasia in the biopsy specimens. Therefore, the inter-
pretation of histological abnormalities in the bladder
biopsies is somewhat controversial. There is a significant
bias in regard to our data taken from non-standardized
reports from multiple pathologists. The high inter- and
intra-pathologist variation indicates that these alterations
are difficult to interpret and provide no reliable clinical
value for the urologist. However, at our institution, all
pathological and cytological specimens were carefully
reviewed by uro-pathologists and well trained cytolo-
gists. Another limitation is that a second TUR was not
performed in the diagnosis and treatment of bladder
tumor in our cases because they were not routinely per-
formed at our institution. No maintenance BCG therapy
or immediate intravesical chemotherapy was performed
in the study period.
Conclusions
Bladder cancer was detected in 26 of 234 cases (11.1%) by
performing multiple biopsies from normal-appearing
urothelium in addition to TUR-BT. In total, 8 cases were
recognized as having more malignant features, including
CIS and multiplicity, due to the biopsy results. The 8
cases had all positive cytology results. The therapeutic
decision was not altered in these 8 cases. Thus, our find-
ings suggest that multiple biopsies from normal-appear-
ing urothelium would not be of benefit and are therefore
unnecessary in patients with negative cytology results.
On the other hand, the positive rate for detecting CIS (N
= 9, 22.0%) in biopsies from suspicious-appearing urothe-
lium was relatively high. Meanwhile, 3 patients with CIS
only detected in the biopsies from suspicious-appearing
urothelium had negative cytology results. In patients with
negative cytology results, suspicious-appearing urothe-
lium would be needed in order to detect CIS because of
staging properties. This result supported the recent EAU
guideline.
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